Literature DB >> 28983794

Somatic Hypermutation Defects in Common Variable Immune Deficiency.

María Belén Almejun1,2, Mercedes Borge3,4.   

Abstract

Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by impaired antibody production and recurrent infections. In the last 20 years, several groups have reported that B cells from CVID patients have an impaired somatic hypermutation (SHM). The reported frequency of this defect among CVID patient cohorts is highly variable and so is the methodology used to evaluate this process. Interestingly, the low level of SHM on B cells from CVID patients has been correlated with the presence of infectious and non-infectious complications. In this review, an overview of the studies regarding SHM in CVID patients is presented. We highlight the importance of SHM studies in CVID patients as a clinical tool due to the reported association with clinical complications by several groups. We also considered SHM measurement useful to guide future investigations in order to identify genetic defects involved in the development of the disease.

Entities:  

Keywords:  CSR; CVID; Clinical complications; IgV; SHM

Mesh:

Year:  2017        PMID: 28983794     DOI: 10.1007/s11882-017-0745-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  50 in total

Review 1.  Managing comorbid complications in patients with common variable immunodeficiency.

Authors:  Mark Ballow
Journal:  Ann Allergy Asthma Immunol       Date:  2013-12       Impact factor: 6.347

2.  Noninfectious complications in patients with pediatric-onset common variable immunodeficiency correlated with defects in somatic hypermutation but not in class-switch recombination.

Authors:  María Belén Almejún; Bárbara Carolina Campos; Virginia Patiño; Miguel Galicchio; Marta Zelazko; Matías Oleastro; Pablo Oppezzo; Silvia Danielian
Journal:  J Allergy Clin Immunol       Date:  2016-10-03       Impact factor: 10.793

3.  Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID).

Authors:  Julie Wang; Charlotte Cunningham-Rundles
Journal:  J Autoimmun       Date:  2005-08       Impact factor: 7.094

Review 4.  Common variable immunodeficiency.

Authors:  M C Sneller
Journal:  Am J Med Sci       Date:  2001-01       Impact factor: 2.378

Review 5.  AID targeting in antibody diversity.

Authors:  Rushad Pavri; Michel C Nussenzweig
Journal:  Adv Immunol       Date:  2011       Impact factor: 3.543

Review 6.  Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions.

Authors:  Helen Chapel; Charlotte Cunningham-Rundles
Journal:  Br J Haematol       Date:  2009-03-30       Impact factor: 6.998

7.  Complex Antigens Drive Permissive Clonal Selection in Germinal Centers.

Authors:  Masayuki Kuraoka; Aaron G Schmidt; Takuya Nojima; Feng Feng; Akiko Watanabe; Daisuke Kitamura; Stephen C Harrison; Thomas B Kepler; Garnett Kelsoe
Journal:  Immunity       Date:  2016-03-03       Impact factor: 31.745

8.  Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects.

Authors:  B Piqueras; C Lavenu-Bombled; L Galicier; F Bergeron-van der Cruyssen; L Mouthon; S Chevret; P Debré; C Schmitt; E Oksenhendler
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

9.  Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.

Authors:  Paula Jane Busse; Samiya Razvi; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2002-06       Impact factor: 10.793

10.  Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).

Authors:  P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.